Laser therapy for onychomycosis in patients with diabetes at risk for foot complications: study protocol for a randomized, double-blind, controlled trial (LASER-1)

Leonie Nijenhuis-Rosien, Nanne Kleefstra, Maurice J Wolfhagen, Klaas H Groenier, Henk J G Bilo, Gijs W D Landman, Leonie Nijenhuis-Rosien, Nanne Kleefstra, Maurice J Wolfhagen, Klaas H Groenier, Henk J G Bilo, Gijs W D Landman

Abstract

Background: In a sham-controlled double-blind trial, we aim to establish the efficacy and safety of the local application of laser therapy in patients with diabetes, onychomycosis and risk factors for diabetes-related foot complications. Onychomycosis leads to thickened and distorted nails, which in turn lead to increased local pressure. The combination of onychomycosis and neuropathy or peripheral arterial disease (PAD) increases the risk of developing diabetes-related foot complications. Usual care for high-risk patients with diabetes and onychomycosis is completely symptomatic with frequent shaving and clipping of the nails. No effective curative local therapies exist, and systemic agents are often withheld due to concerns for side effects and interactions.

Methods/design: The primary aim is to evaluate the efficacy of four sessions of Nd:YAG 1064 nM laser application on the one-year clinical and microbiological cure rate in a randomized, double-blind, sham-controlled design with blinded outcome assessment. Mandatory inclusion criteria are diagnosis of diabetes, risk factors for developing foot ulcers defined as a modified Simm's classification score 1 or 2 and either neuropathy or PAD. A total of 64 patients are randomized to intervention or sham treatment performed by a podiatrist.

Discussion: This study will be the first double-blind study that investigates the effects of local laser therapy on onychomycosis, specifically performed in patients with diabetes with additional risk factors for foot complications.

Trial registration: Clinical trials.gov as NCT01996995 , first received 22 November 2013.

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002;45:S13–7. doi: 10.1007/s00125-002-0859-9.
    1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–62. doi: 10.2337/diacare.28.4.956.
    1. Gupta A, Konnikov N, MacDonald P, Rich P, Rodger N, Edmonds M, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicenter study. Br J Dermatol. 1998;139:665–71. doi: 10.1046/j.1365-2133.1998.02464.x.
    1. Boyko E, Ahroni J, Cohen V, Nelson K, Heagerty P. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the seattle Diabetic Foot Study. Diabetes Care. 2006;29:1202–7. doi: 10.2337/dc05-2031.
    1. Cathcart S, Cantrell W, Elewski B. Onychomycosis and diabetes. J Eur Acad Dermatol Venereol. 2009;23:1119–22. doi: 10.1111/j.1468-3083.2009.03225.x.
    1. Rich P. Onychomycosis and tinea pedis in patients with diabetes. J Am Acad Dermatol. 2000;43:130–8. doi: 10.1067/mjd.2000.110376.
    1. Armstrong D, Holtz K, Wu S. Can the use of a topical antifungal nail lacquer reduce risk for diabetic foot ulceration? results from a randomised controlled pilot study. Int Wound J. 2005;2:166–70. doi: 10.1111/j.1742-4801.2005.00097.x.
    1. Brodell J, Brodell R. Recurrent lymphangitic ellulitis syndrome. Contemp Orthop. 1992;25:461–8.
    1. Cox N, Colver G, Paterson W. Management and morbidity of cellulitis of the leg. J R Soc Med. 1998;91:634–7.
    1. Pierce R, Daugird A. Recurrent leg cellulitis: pathogenesis, prevention and treatment. J Am Board Fam Pract. 1992;5:85–7.
    1. Armstrong D. Is diabetic foot care efficacious or cost-effective? Ostomy Wound Manage. 2001;47:28–32.
    1. Bild D, Shelby J, Sinnock P, Browner W, Braveman P, Showstock J. Lower extremity amputations in people with diabetes: epidemiology and prevention. Diabetes Care. 1989;12:24–9. doi: 10.2337/diacare.12.1.24.
    1. Block P. The diabetic foot ulcer: a complex problem with a simple treatment approach. Mil Med. 1981;146:644–6.
    1. Lavery L, Armstrong D, Vela S, Quebedeaux T, Fleischli J. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med. 1998;158:158–62. doi: 10.1001/archinte.158.2.157.
    1. Smith D, Weinberger M, Katz B. A controlled trial to increase office visits and reduce hospitalization in diabetic patients. J Gen Intern Med. 1987;2:232–8. doi: 10.1007/BF02596446.
    1. Gupta A, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol. 2000;10:379–84.
    1. Karchmer A, Gibbons G. Foot infection in diabetes: evaluation and management. Curr Clin Top Infect Dis. 1994;14:1–22.
    1. Ramsey S, Newton K, Blough D, McCulloch D, Sandhu N, Reiber G, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:383–7. doi: 10.2337/diacare.22.3.382.
    1. Shuster S, Fisher GH, Harris E, Binnell D. The effect of skin disease on self image [proceedings] Br J Dermatol. 1978;99:18–9. doi: 10.1111/j.1365-2133.1978.tb15214.x.
    1. Shuster S. Depression of self-image by skin disease. Acta Derm Venereol Suppl (Stockh) 1991;156:53.
    1. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998;38:702–4. doi: 10.1016/S0190-9622(98)70199-9.
    1. Drake LA, Patrick DL, Fleckman P, Andr J, Baran R, Haneke E, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol. 1999;41:189–96. doi: 10.1016/S0190-9622(99)70047-2.
    1. Warshaw EM, Foster JK, Cham PM, Grill JP, Chen SC. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol. 2007;46:1279–86. doi: 10.1111/j.1365-4632.2007.03362.x.
    1. Robbins J. Treatment of onychomycosis in the diabetic population. J Diabetes Complications. 2003;17:98–104. doi: 10.1016/S1056-8727(02)00199-X.
    1. Apelqvist J, Larrson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab Res Rev. 2000;16:s75–83. doi: 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR139>;2-8.
    1. Singh N, Armstrong D, Lipsky B. Preventing foot ulcers in patients with diabetes. J Am Med Assoc. 2005;293:217–28. doi: 10.1001/jama.293.2.217.
    1. Gupta AK, Simpson FC. New therapeutic options for onychomycosis. Expert Opin Pharmacother. 2012;13:1131–42. doi: 10.1517/14656566.2012.681779.
    1. Anarella J, Toth C, Debello J. Preventing complications in the diabetic patient with toenail onychomycosis. J Am Podiatr Med Assoc. 2001;91:325–8. doi: 10.7547/87507315-91-6-325.
    1. Bhatta AK, Huang X, Keyal U, Zhao JJ. Laser treatment for onychomycosis: a review. Mycoses. 2014;57:734–40. doi: 10.1111/myc.12225.
    1. Arabatzis M, van Coppenraet LEB, Kuijper EJ, de Hoog GS, Lavrijsen AP, Templeton K, et al. Diagnosis of common dermatophyte infections by a novel multiplex real-time polymerase chain reaction detection/identification scheme. Br J Dermatol. 2007;157:681. doi: 10.1111/j.1365-2133.2007.08100.x.
    1. Carney C, Tosti A, Daniel R, Scher R, Rich P, DeCoster J, et al. A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index. Arch Dermatol. 2011;147:1277–82. doi: 10.1001/archdermatol.2011.267.
    1. Nederlandse Internisten Vereeniging. Richtlijn Diabetische voet. Van Zuiden Communications B.V., Alphen aan den Rijn, ISBN-10 90-8523-142-6, 2007.
    1. Rao K, Sankar TK. Long-pulsed Nd:YAG laser-assisted hair removal in Fitzpatrick skin types IV-VI. Lasers Med Sci. 2011;26:623–6. doi: 10.1007/s10103-011-0922-1.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit